Everyone deserves a fair and just opportunity to attain their optimal health and well-being.  For far too long, this ideal has felt out of reach for many individuals living with Sickle Cell Disease (SCD). Sickle Cell Disease – an inherited blood disorder, affects approximately 100,000 individuals in the United States, the majority of whom are Black/African American, and/or Hispanic.

The Centers for Medicare & Medicaid Services (CMS) is committed to fostering innovation while ensuring that people with Medicare have faster and more consistent access to emerging technologies that will improve health outcomes. As part of this commitment, today, CMS announced a proposed Transitional Coverage for Emerging Technologies (TCET) pathway. Today’s announcement includes a proposed procedural notice and several proposed guidance documents that propose a substantial transformation to our approach to coverage reviews and evidence development.   

The Centers for Medicare & Medicaid Services (CMS) and the Health Resources and Services Administration (HRSA) are federal agencies within the U.S. Department of Health and Human Services (HHS) that play important roles in protecting the health and safety of Americans as they engage with the U.S. healthcare system. The agencies share responsibility for overseeing the organ donation, procurement, and transplantation system.

The Centers for Medicare & Medicaid Services (CMS) is committed to ensuring people on Medicare have quicker access to innovative medical technologies for life-threatening or irreversibly debilitating diseases – like cancer and heart disease.